BridgeMD
New treatment option for Androgenic Alopecia
Official title Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia
ClinicalTrials.gov ID: NCT07373054
What this study is testing
What is Topical Minoxidil?
Topical Minoxidil is an investigational medicine, given as an once-daily treatment applied to the skin, being studied as a potential treatment for androgenic alopecia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Androgenic Alopecia(AGA) is a highly prevalent condition for which existing pharmacological and surgical interventions present limitations and side effects, creating a clinical need for safer and more effective therapies. In response, human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60, men only
You may be able to join if
- Male, aged 18 to 60 years (inclusive), in good general health.
- Clinical diagnosis of androgenetic alopecia (AGA) according to the 2023 Chinese Clinical Practice Guideline: Diagnosis and Treatment of Androgenetic...
- Able to fully understand the study's content, procedures, potential benefits, and risks, and willing to provide written informed consent prior to any...
- Agrees to comply with the study protocol and refrain from using any other treatments for alopecia for the duration of the study.
You likely can't join if
- Unwilling or unable to provide written informed consent.
- History of any malignancy within the past 5 years (except for adequately treated non-scalp basal cell carcinoma or squamous cell carcinoma in situ).
- Hypotension (blood pressure \< 90/60 mmHg) documented within 1 month prior to screening, or uncontrolled hypertension within 3 months prior to...
- Known history of any systemic disease that may affect hair growth or confound study assessments (e.g., HIV infection, connective tissue disease...
- Known history of other forms of non-androgenetic alopecia (e.g., diffuse alopecia, alopecia areata, cicatricial alopecia).
- History of major organ dysfunction, significant autoimmune disease, or immunodeficiency.
See the full eligibility criteria
- Male, aged 18 to 60 years (inclusive), in good general health.
- Clinical diagnosis of androgenetic alopecia (AGA) according to the 2023 Chinese Clinical Practice Guideline: Diagnosis and Treatment of Androgenetic Alopecia, with a disease duration of less than 5 years and a...
- Able to fully understand the study's content, procedures, potential benefits, and risks, and willing to provide written informed consent prior to any study-specific procedures.
- Agrees to comply with the study protocol and refrain from using any other treatments for alopecia for the duration of the study.
- Unwilling or unable to provide written informed consent.
- History of any malignancy within the past 5 years (except for adequately treated non-scalp basal cell carcinoma or squamous cell carcinoma in situ).
- Hypotension (blood pressure \< 90/60 mmHg) documented within 1 month prior to screening, or uncontrolled hypertension within 3 months prior to screening (defined as failure to achieve a target of \< 140/90 mmHg while on...
- Known history of any systemic disease that may affect hair growth or confound study assessments (e.g., HIV infection, connective tissue disease, inflammatory bowel disease, hypothyroidism, iron deficiency anemia...
- Known history of other forms of non-androgenetic alopecia (e.g., diffuse alopecia, alopecia areata, cicatricial alopecia).
- History of major organ dysfunction, significant autoimmune disease, or immunodeficiency.
- Known coagulation disorders, current use of anticoagulant or antiplatelet therapy (except low-dose aspirin), thrombophilia, or inherited bleeding disorders.
- Treatment with chemotherapy, cytotoxic drugs, scalp radiation, or laser/surgical hair restoration within 12 months prior to screening.
- History of hair transplantation, or need for long-term use of wigs, hairpieces, or hair bonding agents during the trial.
- History of severe or multiple drug allergies, atopy, known allergy to local anesthetics, or planned desensitization therapy during the study period.
- Presence of any active dermatological condition in the target scalp area that could interfere with evaluation (e.g., infection, seborrheic dermatitis, psoriasis, eczema, folliculitis, open wounds, scars, or atrophy).
- Participation in another treatment clinical trial within 4 weeks prior to screening (except for non-treatment studies or participants who only signed the informed consent form without receiving any investigational...
- Any other medical or psychiatric condition that, in the judgment of the investigator, would compromise the subject's safety, compliance, or suitability for study participation.
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.